Researchers have determined that disabling the protein eEF2K may be a valuable therapeutic approach to tackling established solid tumours, at least for some types of cancers. It is thought that blocking eEF2K function may be more appropriate in later stages of tumour progression as the inhibition of eEF2K has the potential to promote initial cancer-related processes.
The role of eEF2K in the fight against cancer